Position of the Transparency Council – Arexvy (recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted)
At its meeting on 13 May 2025, the Transparency Council adopted position No. 59/2025 on the appraisal of the vaccine Arexvy (recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted) for the indication: active immunization for the prevention of lower respiratory disease caused by respiratory syncytial virus (RSV) in adults aged 60 years and older.